Subgroups
Bayer HealthCare
-
Thursday - September 10, 2009
European Multiple Sclerosis Congress ECTRIMS:
Recent Research Supports the Importance of Starting Treatment Early in Patients with Multiple Sclerosis (MS)
New data show impact of hidden symptoms in early MS
-
Thursday - September 10, 2009
New data presented at European Multiple Sclerosis Congress ECTRIMS:
Betaferon® may play a role in the protection of brain tissue
-
Friday - September 4, 2009
Mastering the challenge
Conquering the summit unaided
Diabetic Geri Winkler plans to scale Cho Oyu without the help of supplemental oxygen
-
Thursday - September 3, 2009
Bayer and Algeta Enter Global Agreement for Development and Commercialization of Treatment for Bone Metastases in Cancer Patients
Phase III compound represents potential therapy for life-threatening condition
-
Wednesday - September 2, 2009
Bayer Acquires Two Prescription Dermatology Product Lines from SkinMedica in the U.S.
Bayer subsidiary Intendis expands presence in the U.S. / Asset purchase agreement signed for marketed prescription products Desonate® and NeoBenz® Micro
-
Sunday - August 30, 2009
Bayer Committed to Prevention of Arterial Thrombosis:
Bayer Completes Enrollment into Major Phase III Study with Rivaroxaban (ROCKET AF)
ROCKET AF study compares rivaroxaban to warfarin in the prevention of stroke and non-CNS systemic embolism in patients with Atrial Fibrillation / Bayer Schering Pharma supports Thrombosis Research Institute’s launch of GARFIELD – a global patient Registry to evaluate ‘real life’ outcomes in the prevention of stroke in patients with Atrial Fibrillation / Fast Track designation for rivaroxaban development program in the secondary prevention of cardiovascular events in patients with Acute Coronary Syndrome recognizes high unmet medical need.
-
Wednesday - August 19, 2009
New Levitra® formulation submitted for registration in the EU
First orodispersible tablet for the treatment of erectile dysfunction
-
Wednesday - August 5, 2009
Proton Pump Inhibitor omeprazole available soon without prescription:
New therapeutic option for heartburn
Bayer Consumer Care New Zealand will launch omeprazole under the Losec® brand without prescription / Bayer will market OTC omeprazole based on an exclusive licensing agreement with AstraZeneca
-
Wednesday - July 29, 2009
Interim report for the second quarter of 2009:
Bayer robust in a difficult environment
HealthCare strong – further growth at CropScience – MaterialScience stabilized / Group sales EUR 8,009 million (minus 5.9 percent) / EBITDA before special items EUR 1,765 million (minus 6.9 percent) / EBIT before special items EUR 1,101 million (minus 11.8 percent) / Group net income EUR 532 million (minus 7.3 percent) / Net cash flow EUR 1,399 million (plus 57.4 percent) / Earnings targets for full year 2009 confirmed
-
Wednesday - July 22, 2009
Nexavar® in Combination with Chemotherapy Shown To Extend Progression-Free Survival in Patients with Advanced Breast Cancer
Statistically Significant Results Reported from a Phase II Study Combining Two Oral Cancer Therapies
-
Tuesday - July 14, 2009
New Drug Application for Rivaroxaban in the U.S.:
Update on Status of Rivaroxaban Complete Response Letter From U.S. FDA
-
Monday - July 13, 2009
International Conference on Alzheimer´s Disease (ICAD):
Bayer presents positive Phase II data with florbetaben
Potential to visualize beta-Amyloid plaques in Patients with Alzheimer’s disease demonstrated / Florbetaben may innovate the diagnostic capabilities
-
Friday - July 10, 2009
Proton Pump Inhibitor omeprazole available soon without prescription:
New therapeutic option for heartburn
OTC-status in Germany effective as of August 1st, 2009 / Bayer Vital will launch omeprazole under the Antra® brand without prescription / Bayer will market OTC omeprazole based on an exclusive licensing agreement with AstraZeneca
-
Thursday - July 9, 2009
Expansion of diabetes portfolio in growth market China:
Bayer acquires exclusive rights to Bioton’s insulin SciLin®
-
Wednesday - July 8, 2009
Bayer submits first-in-class estradiol-based oral contraceptive for approval in the U.S.
FDA approval requested for oral contraception and treatment of heavy and/or prolonged menstrual bleeding
-
Wednesday - July 1, 2009
Bayer files patent infringement lawsuit against Teva
-
Monday - June 29, 2009
Implementation of R&D Strategy:
Bayer Schering Pharma Extends Research Portfolio in the Field of Cancer-Related Targets
License Agreement with Celera Corporation on five cancer target molecules
-
Friday - June 12, 2009
Bayer completes Phase II Study on BAY 94-9172 in Alzheimer’s Disease Imaging
Diagnostic Imaging Using Positron Emission Tomography (PET)
-
Wednesday - June 10, 2009
Twelve countries in thirty-one days
Discovering Europe on two wheels
Diabetic Paul Farelly finished his European Cycle Challenge from Portsmouth to Istanbul
-
Tuesday - June 2, 2009
Bayer HealthCare and Genzyme Finalize Strategic Alliance Agreement
Search
Publications
Stockholders' Newsletter
Annual Report
Sustainable Development Report
The Bayer Climate Program
research – The Bayer Scientific Magazine
Publications Overview
Newsletter
EventsFriday, February 26, 2010
Annual Report 2009 / Financial News Conference Full Year 2009
Contact: Günter Forneck
Additional Press Events
Investor Relations Events
Sport Events
BayKomm Events
Download Center - Selection